Risdiplam, a small molecule that acts as an SMN2 splicing modifier, received its approval in 2020 for all SMA types in patients 2 years of age and up after demonstrating functional improvements in patients. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.